Birth Outcomes In Eswatini After Transition To Dolutegravir-Based Treatment
The goal of this observational study is to assess the birth outcomes of HIV-positive women delivering in hospitals in Eswatini who are receiving dolutegravir (DTG) or other anti-retroviral (ARV) drug regimens. The main question the study aims to answer is, what is the proportion of neural tube defects among live and stillborn infants delivered by:
* HIV-positive women on DTG at conception
* HIV-negative women
* HIV-positive women on non-DTG ARV at conception
Participants will be interviewed for information on HIV testing and antiretroviral therapy history, other medical history of selected conditions (e.g., diabetes, malaria, TB) and potential birth defect exposures. Photographs will be taken of the infants. Data on mothers' pregnancy history, birth outcomes, and HIV and ARV information (as applicable) will be collected from patient records.
Neural Tube Defects
Congenital Abnormalities
Teratogens